Investor Presentaiton
Investor Newsletter ISSUE 09
03
Firehawk® Regulatory Approval in Pakistan
On September 8, MicroPort® announced that its in-house developed Firehawk®
received approval from the Drug Regulatory Authority of Pakistan ("DRAP").
Firehawk® is MicroPort's third generation drug-eluting stent ("DES"),
used for the treatment of coronary artery stenosis and occlusion after Firebird®
Rapamycin-Eluting Coronary Stent and Firebird2° Rapamycin-Eluting Coronary
CoCr Stent. As the world's lowest drug dosage stent, Firehawk® combines the
merits of bare metal stents and DES. It adopts unique in-groove abluminal
coating design and target-eluting technique, which allow Firehawk® to achieve
the same clinical efficacy with significantly low drug loading, benefiting
vascular early healing.
Pakistan is the sixth most populous country in the world.
Pakistani population has one of the highest risks of coronary
heart disease in the world. In Pakistan, 30 to 40 percent of
all deaths can be attributed to cardiovascular diseases.
The coronary heart disease death in Pakistan has
reached about 200,000 per year. With Firehawk®'s
regulatory approval in Pakistan, MicroPort® will
offer more ideal solutions to local patients.
Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System
MicroPortView entire presentation